Prescription Claims for Immunomodulator and Anti-Inflammatory Drugs among Persons with Ehlers-Danlos Syndromes.

To our knowledge, our study is the first study to examine the full range of IMD drug prescription claim trends among persons with EDS. We believe our research findings can have notable diagnostic and management implications for EDS patients, who present with multiple co-morbidities and generally require a more granular assessment of their medical conditions. This article is protected by copyright. All rights reserved.